ADELAIDE, Australia I July 29, 2013 I Bionomics Limited (ASX:BNO) (BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
“The initiation of this safety program is a major milestone in the drug development process of BNC101,” said Dr Deborah Rathjen, Bionomics CEO & Managing Director. “The fact that Bionomics achieved this milestone less than a year from the acquisition of this asset is a demonstration of our commitment to being a leader in the cancer stem cell therapeutic space.”
BNC101, a humanized monoclonal antibody targeting LGR5, has demonstrated functional activity against Cancer Stem Cells (CSCs) from primary colorectal cancer (CRC) patient samples. In preclinical studies, BNC101 significantly reduces CSC frequency in vivo and prevents tumour re-growth in long term studies. BNC101 also increases survival and inhibits weight loss in a cachexic CRC tumour model. To date BNC101 has shown no evidence of toxicity in preliminary safety analyses.
About Bionomics Limited
Bionomics (ASX:BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders, several of which are in or approaching clinical development stage. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.
BNC105, which is undergoing Phase II clinical development for the treatment in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.
Bionomics’ discovery and development activities are driven by its four proprietary technology platforms: Angene(R), a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore(R), a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX(R), a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery(TM), which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics’ pipeline and underpin its established business strategy of securing partners for its key compounds.
www.bionomics.com.au
SOURCE: Bionomcs
Post Views: 744
ADELAIDE, Australia I July 29, 2013 I Bionomics Limited (ASX:BNO) (BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
“The initiation of this safety program is a major milestone in the drug development process of BNC101,” said Dr Deborah Rathjen, Bionomics CEO & Managing Director. “The fact that Bionomics achieved this milestone less than a year from the acquisition of this asset is a demonstration of our commitment to being a leader in the cancer stem cell therapeutic space.”
BNC101, a humanized monoclonal antibody targeting LGR5, has demonstrated functional activity against Cancer Stem Cells (CSCs) from primary colorectal cancer (CRC) patient samples. In preclinical studies, BNC101 significantly reduces CSC frequency in vivo and prevents tumour re-growth in long term studies. BNC101 also increases survival and inhibits weight loss in a cachexic CRC tumour model. To date BNC101 has shown no evidence of toxicity in preliminary safety analyses.
About Bionomics Limited
Bionomics (ASX:BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders, several of which are in or approaching clinical development stage. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.
BNC105, which is undergoing Phase II clinical development for the treatment in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.
Bionomics’ discovery and development activities are driven by its four proprietary technology platforms: Angene(R), a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore(R), a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX(R), a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery(TM), which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics’ pipeline and underpin its established business strategy of securing partners for its key compounds.
www.bionomics.com.au
SOURCE: Bionomcs
Post Views: 744
